Slc13a2 Cas9-CKO Strategy

Designer:Xueting Zhang
Reviwer:Yanhua Shen
Date:2020-02-13

Project Overview

Project Name	***Slc13a2***
Project type	**Cas9-CKO**
Strain background	**C57BL/6JGpt**

Conditional Knockout strategy

This model will use CRISPR/Cas9 technology to edit the *Slc13a2* gene. The schematic diagram is as follows:



Technical routes

- The *Slc13a2* gene has 1 transcript. According to the structure of *Slc13a2* gene, exon2-exon6 of *Slc13a2-201* (ENSMUST00000001122.5) transcript is recommended as the knockout region.The region contains 761bp coding sequence. Knock out the region will result in disruption of protein function.

- In this project we use CRISPR/Cas9 technology to modify *Slc13a2* gene. The brief process is as follows:CRISPR/Cas9 system and Donor were microinjected into the fertilized eggs of C57BL/6JGpt mice.Fertilized eggs were transplanted to obtain positive F0 mice which were confirmed by PCR and sequencing. A stable F1 generation mouse model was obtained by mating positive F0 generation mice with C57BL/6JGpt mice.

- The flox mice will be knocked out after mating with mice expressing Cre recombinase, resulting in the loss of function of the target gene in specific tissues and cell types.

Notice

- According to the existing MGI data,Mice homozygous for a knock-out allele exhibit increased Kreb cycle intermediates in the urine but otherwise have normal kidney function and response to ischemia-reperfusion injury and caloric restriction.
- *Slc13a2os* gene will be destroyed in this strategy.
- The *Slc13a2* gene is located on the Chr11. If the knockout mice are crossed with other mice strains to obtain double gene positive homozygous mouse offspring, please avoid the two genes on the same chromosome.
- This Strategy is designed based on genetic information in existing databases.Due to the complexity of biological processes, all risk of loxp insertion on gene transcription, RNA splicing and protein translation cannot be predicted at existing technological level.

Gene information （NCBI）

集萃药康 GemPharmatech

Slc13a2 solute carrier family 13 (sodium-dependent dicarboxylate transporter), member 2 [*Mus musculus* (house mouse)]

Gene ID: 20500, updated on 29-Oct-2019

Summary

Official Symbol	Slc13a2 provided by MGI
Official Full Name	solute carrier family 13 (sodium-dependent dicarboxylate transporter), member 2 provided by MGI
Primary source	MGI:MGI:1276558
See related	Ensembl:ENSMUSG00000001095
Gene type	protein coding
RefSeq status	VALIDATED
Organism	Mus musculus
Lineage	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae; Murinae; Mus; Mus
Also known as	Nadc1; Nadc-1; mNaDC-1
Expression	Biased expression in colon adult (RPKM 77.1), large intestine adult (RPKM 68.5) and 3 other tissues See more
Orthologs	human all

Genomic context

Location: 11 B5; 11 46.74 cM

See Slc13a2 in Genome Data Viewer

Exon count: 14

Annotation release	Status	Assembly	Chr	Location
108	current	GRCm38.p6 (GCF_000001635.26)	11	NC_000077.6 (78397276..78422281, complement)
Build 37.2	previous assembly	MGSCv37 (GCF_000001635.18)	11	NC_000077.5 (78210778..78235687, complement)

Transcript information（Ensembl）

The gene has 1 transcript,and the transcript is shown below:

Name	Transcript ID	bp	Protein	Biotype	CCDS	UniProt	Flags
Slc13a2-201	ENSMUST00000001122.5	2412	586aa	Protein coding	CCDS25103	Q9ES88	TSL:1 GENCODE basic APPRIS P1

The strategy is based on the design of *Slc13a2-201* transcript,The transcription is shown below



Genomic location distribution



Protein domain



Mouse phenotype description(MGI)



Phenotypes affected by the gene are marked in blue.Data quoted from MGI database(http://www.informatics.jax.org/).

According to the existing MGI data,Mice homozygous for a knock-out allele exhibit increased Kreb cycle intermediates in the urine but otherwise have normal kidney function and response to ischemia-reperfusion injury and caloric restriction.

集萃药康
GemPharmatech

If you have any questions, you are welcome to inquire.

Tel: 400-9660890

集萃药康生物科技
GemPharmatech Co.,Ltd